XML 59 R50.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Commitments and Contingencies (Details) |  |  |  |  | 1 Months Ended | 6 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Sep. 01, 2021 USD ($) | Jul. 06, 2021 USD ($) | Apr. 12, 2021 shares | Jan. 05, 2021 USD ($) shares | Jan. 27, 2022 | Apr. 30, 2021 USD ($) | Dec. 31, 2020 USD ($) | Jul. 31, 2020 USD ($) | Apr. 17, 2020 | Jun. 30, 2022 USD ($) shares | Dec. 31, 2021 USD ($) shares | Feb. 01, 2022 USD ($) | Dec. 31, 2021 EUR (€)
Commitments and Contingencies (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Employment agreement, description |  |  |  |  |  |  |  |  | The Employment Agreement provided for a base salary of $120,000 and 152,619 of vested shares of the Company’s common stock in April 2020. In addition, Mr. Weisblum shall be eligible to earn a bonus, subject to the sole discretion of the Company’s Board of Directors (“Board”). |  |  |  |
License fee |  | $ 10,000 |  |  |  |  |  | $ 10,000 |  |  |  |  |
Commercial sale term |  |  |  |  |  |  |  |  |  | 10 years | 10 years |  |
License agreement expire |  |  |  |  |  |  |  |  |  | 15 years | 15 years |  |
Sublicense income, description |  |  |  |  |  |  |  |  |  | The Company or Company affiliates shall pay to UMB a percentage of all income received from its sublicensee as follows: (i) 25% of the Company’s sublicense income which is receivable with respect to any sublicense that is executed before the filing of an NDA (or foreign equivalent) for the first licensed product; and (b) 15% of the Company’s sublicense income which is receivable with respect to any sublicense that is executed after the filing of an NDA (or foreign equivalent) for the first licensed product. | The Company or Company affiliates shall pay to UMB a percentage of all income received from its sublicensee as follows: (i) 25% of the Company’s sublicense income which is receivable with respect to any sublicense that is executed before the filing of an NDA (or foreign equivalent) for the first licensed product; and (b) 15% of the Company’s sublicense income which is receivable with respect to any sublicense that is executed after the filing of an NDA (or foreign equivalent) for the first licensed product. |  |
License agreement, description |  |  |  |  |  |  |  |  |  | the Company shall pay UMB; (i) a license fee, (ii) certain event-based milestone payments (see below for payment terms), (iii) royalty payments depending on net revenues (see below for payment terms), and (iv) a tiered percentage of sublicense income. The Company shall pay to UMB a license fee of $75,000, payable as follows: (a) $25,000 shall be due within 30 days following the effective date; and (b) $50,000 on or before the first anniversary of the effective date. The license fee is non-refundable and is not creditable against any other fee, royalty or payment. The Company shall be responsible for payment of all patent expenses in connection with preparing, filing, prosecution and maintenance of patents or patent applications relating to the patent rights. The Company paid $25,000 license fee on February 17, 2021 which was recorded as prepaid expense and is being amortized over the 15-year term. The Company recognized amortization expense of $4,375 in 2021. During the six months ended June 30, 2022, the Company recognized amortization expense of $2,500. At December 31, 2021, prepaid expense and other current assets – current amounted $5,000 and prepaid expense – non-current amounts $15,625. At June 30, 2022, prepaid expense and other current assets – current amounted $5,000 and prepaid expense – non-current amounts $13,125 as reflected in the accompanying condensed consolidated balance sheets. | the Company shall pay UMB; (i) a license fee, (ii) certain event-based milestone payments (see below for payment terms), (iii) royalty payments depending on net revenues (see below for payment terms), and (iv) a tiered percentage of sublicense income. The Company shall pay to UMB a license fee of $75,000, payable as follows: (a) $25,000 shall be due within 30 days following the effective date; and (b) $50,000 on or before the first anniversary of the effective date. The license fee is non-refundable and is not creditable against any other fee, royalty or payment. The Company shall be responsible for payment of all patent expenses in connection with preparing, filing, prosecution and maintenance of patents or patent applications relating to the patent rights. The Company paid $25,000 license fee on February 17, 2021 which was recorded as prepaid expense and is being amortized over the 15-year term. The Company recognized amortization expense of $4,375 during the year ended December 31, 2021. At December 31, 2021, prepaid expense and other current assets – current amounted $5,000 and prepaid expense – non-current amounts $15,625 as reflected in the accompanying consolidated balance sheets. |  |
Royalty payments, description |  |  |  |  |  |  |  |  |  | Royalty Payments Terms: (i)3% on sales of licensed products (as defined in the Master License Agreement) during the applicable calendar year for sales less than $50,000,000; and (ii)5% on sales of licensed products during the applicable calendar year for sales greater than $50,000,000; and | (i)3% on sales of licensed products (as defined in the Master License Agreement) during the applicable calendar year for sales less than $50,000,000; and |  |
Recognized amortization expenses |  |  |  |  |  |  |  |  |  |  | $ 92,095 |  |
Payment of sponsored research amount |  |  |  |  |  |  |  |  |  |  | 838 |  |
Prepaid expenses – non-current |  |  |  |  |  |  |  |  |  |  | 11,034 |  |
Non-refundable cash payment |  |  |  | $ 500,000 |  |  |  |  |  | $ 500,000 | $ 500,000 |  |
Net sale percentage |  |  |  |  |  |  |  |  |  | 2.00% | 2.00% |  |
Licensor share (in Shares) | shares |  |  | 500 | 500 |  |  |  |  |  | 500 | 500 |  |
Aggregate of converted shares (in Shares) | shares |  |  | 625,000 | 625,000 |  |  |  |  |  | 625,000 | 625,000 |  |
Revenue term |  |  |  | 15 years |  |  |  |  |  | 15 years | 15 years |  |
Number of voting shares (in Shares) | shares |  |  |  |  |  |  |  |  |  |  | 20,000 |  |
Reverse stock split vote, description |  |  |  |  |  |  |  |  |  | In addition, each share of the Series M Convertible Preferred Stock shall be convertible, at any time after the earlier of (i) the date that the Reverse Stock Split Vote is approved by Aikido’s stockholders and (ii) December 31, 2021, at the option of the holder, into such number of shares of Aikido’s common stock determined by dividing the Stated Value by the Conversion Price. “Stated Value” means $1,000. “Conversion Price” means $0.80, subject to adjustment.Prior to the April 12, 2021, issuance of the common stock in lieu of the Series M Convertible Preferred Stock as discussed above, the Company valued the 500 Series M Convertible Preferred stock which was equivalent into Aikido’s 625,000 shares of common stock at a fair value of $0.85 per common share or $531,250 based quoted trading price of Aikido’s common stock on the date of grant. The Company recorded an equity investment of $531,250 (see Note 3) and deferred revenue of $531,250 to be recognized as revenues over the term of the license. | In addition, each share of the Series M Convertible Preferred Stock shall be convertible, at any time after the earlier of (i) the date that the Reverse Stock Split Vote is approved by Aikido’s stockholders and (ii) December 31, 2021, at the option of the holder, into such number of shares of Aikido’s common stock determined by dividing the Stated Value by the Conversion Price. “Stated Value” means $1,000. “Conversion Price” means $0.80, subject to adjustment.Prior to the April 12, 2021 issuance of the common stock in lieu of the Series M Convertible Preferred Stock as discussed above, the Company valued the 500 Series M Convertible Preferred stock which was equivalent into Aikido’s 625,000 shares of common stock at a fair value of $0.85 per common share or $531,250 based quoted trading price of Aikido’s common stock on the date of grant. The Company recorded an equity investment of $531,250 (see Note 3) and deferred revenue of $531,250 to be recognized as revenues over the term of the license. |  |
Deferred revenue |  |  |  |  |  |  |  |  |  | $ 1,031,250 | $ 1,031,250 |  |
Cash received |  |  |  |  |  |  |  |  |  | 500,000 | 500,000 |  |
Securities received |  |  |  |  |  |  |  |  |  | 531,250 | 531,250 |  |
Recognized revenues |  |  |  |  |  |  |  |  |  | 34,375 | 68,750 |  |
Recognized revenue |  |  |  |  |  |  |  |  |  |  | 68,750 |  |
Revenue long term portion amounts |  |  |  |  |  |  |  |  |  | $ 859,375 | $ 893,750 |  |
Consideration fee payable percentage |  |  |  |  |  |  |  |  |  | 110.00% | 110.00% |  |
Upfront license fees |  |  |  |  |  | $ 50,000 |  |  |  | $ 50,000 | $ 50,000 |  |
First commercial sale |  |  |  |  |  |  |  |  |  | 10 years | 10 years |  |
Agreement shall expire |  |  |  |  |  |  |  |  |  | 15 years | 15 years |  |
Recognized revenues |  |  |  |  |  |  |  |  |  |  | $ 2,514 |  |
Deferred revenue – current portion |  |  |  |  |  |  |  |  |  | $ 72,102 | 72,102 |  |
Deferred revenue long-term |  |  |  |  |  |  |  |  |  |  | 44,134 |  |
Total fee |  |  |  |  |  |  |  |  |  |  | 507,602 |  | € 433,885
Payment, description |  |  |  |  |  |  | In December 2020, the Company paid the first payment of $101,520 which was recorded to prepaid expense and other current assets – current of which approximately $22,318 was amortized in fiscal 2020. In September 2021, the Company notified Maastricht University of Netherlands for an early termination of this agreement. Maastricht University of Netherlands has not reached the second phase which is to obtain approval from ethical committee. The Company has no further obligation after the termination. During the year ended December 31, 2021, the Company amortized the remaining prepaid expense of $79,202. |  |  |  |  |  |
Sponsored study agreement, description |  |  |  | The total cost under the Sponsored Study Agreement shall not exceed $81,474 which is payable in two equal installments of $40,737 upon execution of the Sponsored Study Agreement and $40,737 upon completion of the project with an estimated project timeline of nine months. The Company paid $40,737 on January 13, 2021 which was recorded in prepaid expense to be amortized over the nine-month period. Currently, the project has not been completed due to the delays cause by the Covid-19 pandemic. During the year ended December 31, 2021, the Company fully amortized the prepaid expense of $40,737. |  |  |  |  |  |  |  |  |
Sublicense amount paid |  |  |  |  |  |  |  |  |  | $ 342,850 | $ 342,850 |  |
Sponsored research agreement, description |  |  |  |  |  |  |  |  |  | The Company paid the first payment of $40,000 pursuant to the payment schedule on the Sponsored Research Agreement on June 15, 2021, second payment of $40,000 on September 9, 2021 and $20,570 on November 18, 2021, third payment of $60,570 on March 1, 2022, which were recorded to prepaid expense and other current assets – current to be amortized over the two-year period. In 2021, the Company amortized $92,855 of the prepaid expense. During the six months ended June 30, 2022, the Company amortized $68,285 of the prepaid expense leaving a prepaid asset of $0 at June 30, 2022. | The Company paid the first payment of $40,000 pursuant to the payment schedule on the Sponsored Research Agreement on June 15, 2021, second payment of $40,000 on September 9, 2021 and $20,570 on November 18, 2021 which were recorded to prepaid expense and other current assets – current to be amortized over the two-year period. During the year ended December 31, 2021, the Company amortized $92,855 of the prepaid expense leaving a prepaid asset of $7,715 at December 31, 2021. |  |
Prepaid expense leaving a prepaid asset |  |  |  |  |  |  | $ 241,091 |  |  | $ 99,939 | $ 145,324 |  |
Company paid cash | $ 92,095 |  |  |  |  |  |  |  |  |  | 5,000 |  |
Payment of university |  |  |  |  |  |  |  |  |  | 5,000 | $ 5,000 |  |
Risk free interest rate |  |  |  |  |  |  |  |  |  |  | 0.50% |  |
Expected dividend yield |  |  |  |  |  |  |  |  |  |  | 0.00% |  |
Expected term |  |  |  |  |  |  |  |  |  |  | 5 years |  |
Expected volatility |  |  |  |  |  |  |  |  |  |  | 169.00% |  |
Deferred compensation balance |  |  |  |  |  |  |  |  |  | 35,782 |  |  |
Prepaid expense and other current assets |  |  |  |  |  |  |  |  |  | 838 | $ 838 |  |
Prepaid expenses non-current |  |  |  |  |  |  |  |  |  | 10,615 | 11,034 |  |
Non refundable fees |  |  |  |  |  |  |  |  |  | 2,500 |  |  |
Deferred revenue current portion |  |  |  |  |  |  |  |  |  | 68,750 | 68,750 |  |
Deferred revenue long-term portion |  |  |  |  |  |  |  |  |  | 42,458 | $ 893,750 |  |
Company paid second payment |  |  |  |  |  |  |  |  |  |  |  | $ 50,000 |
Agreement, description |  |  |  |  |  |  |  |  |  |  | In 2021, the Company paid $5,000 related to this agreement. During the six months ended June 30, 2022, the Company paid $10,000 related to this agreement. |  |
Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Salary was increased |  |  |  |  |  |  |  |  |  | 120,000 | $ 120,000 |  |
Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Salary was increased |  |  |  |  |  |  |  |  |  | 180,000 | 180,000 |  |
Sublicense Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Sublicense income, percentage |  |  |  |  |  | 25.00% |  |  |  |  |  |  |
Sublicense agreement amount paid |  |  |  |  |  | $ 12,500 |  |  |  |  |  |  |
Recognized amortization expenses |  |  |  |  |  |  |  |  |  |  | 628 |  |
Recognized revenues |  |  |  |  |  |  |  |  |  | 1,676 | 2,514 |  |
Deferred revenue – current portion |  |  |  |  |  |  |  |  |  |  | $ 3,352 |  |
Amortization expense |  |  |  |  |  |  |  |  |  | 419 |  |  |
Deferred revenue current portion |  |  |  |  |  |  |  |  |  | $ 3,352 |  |  |
Columbia University [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Sponsored research agreement, description |  |  |  |  |  |  |  |  |  | If the Company elects to exercise the option, both parties will commence negotiation of a license agreement and will execute a license agreement no later than 3 months after the dated of the exercise of the option. Columbia University and the Company will work towards developing a therapeutic treatment for patients suffering from Alzheimer’s disease to post-traumatic stress disorder. During a one-year period from the date of this agreement, the Company shall pay a total of $1,436,082 to Columbia University for the support of the research according to the payment schedule as follows: (i) 30% at signing, (ii) 30% at four and half months after the start of the project, (iii) 30% at nine months after the start of the project and, (iv)10% at completion of the project. The Company paid the first payment of $430,825 in November 2021 which was recorded to prepaid expense and other current assets – current to be amortized over the estimated project timeline of twelve months. In 2021, the Company amortized $359,021 of the prepaid expense. During the six months ended June 30, 2022, the Company amortized the remaining prepaid expense of $71,804. As of June 30, 2022 and December 31, 2021, prepaid expense related to the sponsored research agreement were $0 and $71,804, respectively. | If the Company elects to exercise the option, both parties will commence negotiation of a license agreement and will execute a license agreement no later than 3 months after the dated of the exercise of the option. Columbia University and the Company will work towards developing a therapeutic treatment for patients suffering from Alzheimer’s disease to post-traumatic stress disorder. During a one-year period from the date of this agreement, the Company shall pay a total of $1,436,082 to Columbia University for the support of the research according to the payment schedule as follows: (i) 30% at signing, (ii) 30% at four and half months after the start of the project, (iii) 30% at nine months after the start of the project and, (iv)10% at completion of the project. The Company paid the first payment of $430,825 in November 2021 which was recorded to prepaid expense and other current assets – current to be amortized over the estimated project timeline of twelve months. During the year ended December 31, 2021, the Company amortized $359,021 of the prepaid expense. As of December 31, 2021, prepaid expense related to the sponsored research agreement was $71,804. |  |
Prepaid expense leaving a prepaid asset |  |  |  |  |  |  |  |  |  |  | $ 7,715 |  |
Dr. James Kuo [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Employment agreement, description |  |  |  |  | James Kuo entered into an employment agreement (“Kuo Employment Agreement”) for Dr. Kuo to serve as the Vice President of Research & Development. The Kuo Employment Agreement shall be effective as of the date of the agreement and shall automatically renew for a period of one year at every anniversary of the effective date, with the same terms and conditions, unless either party provides written notice of its intention not to extend the term of the Kuo Employment Agreement at least thirty days’ prior to the applicable renewal date. Dr. Kuo shall be paid an annual base salary of $30,000. For each twelve-month period of his employment, Dr. Kuo shall be entitled to a bonus whereby amount and terms shall be in the sole and absolute discretion of the Board of Directors (“Board”) and shall be payable at the Company’s sole option in stock or in cash. In addition, an aggregate of 16,000 incentive stock options were granted under the 2020 Plan to Dr. Kou, exercisable at $10.00 per share and expires on January 31, 2032. The stock options vest as follows: (i) 6,000 stock options upon issuance; (ii) 5,000 vests on October 31, 2022 and; (iii) 5,000 vests on October 31, 2023. |  |  |  |  |  |  |  |
Stock option (in Shares) | shares |  |  |  |  |  |  |  |  |  | 16,000 |  |  |
Fair value of stock option |  |  |  |  |  |  |  |  |  | $ 94,914 |  |  |
Risk free interest rate |  |  |  |  |  |  |  |  |  | 1.18% |  |  |
Expected dividend yield |  |  |  |  |  |  |  |  |  | 0.00% |  |  |
Expected term |  |  |  |  |  |  |  |  |  | 2 years |  |  |
Expected volatility |  |  |  |  |  |  |  |  |  | 117.00% |  |  |
Fair value of the unvested stock option |  |  |  |  |  |  |  |  |  | $ 59,322 |  |  |
Stock-based Compensation |  |  |  |  |  |  |  |  |  | 23,540 |  |  |
Deferred compensation balance |  |  |  |  |  |  |  |  |  | 35,782 |  |  |
Aikido [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue current portion |  |  |  |  |  |  |  |  |  |  | 3,352 |  |
Deferred revenue long-term portion |  |  |  |  |  |  |  |  |  |  | 44,134 |  |
Master License Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront license fees |  |  |  |  |  |  |  |  |  | $ 1,900,000 | $ 1,900,000 |  |
JV Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Details) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Pursuant terms, description |  |  |  |  |  |  |  |  |  | Pursuant to the terms of the JV Agreement, (A) the Company shall contribute (1) $225,000 and (2) its expertise and the expertise of its science advisory board and (B) ZTI shall contribute (1) certain rights to certain of its patented technology as set forth in the JV Agreement, (2) a license to the know-how and trade secrets with respect to its Z-pod™ technology for the loading and release of ketamine, (3) ketamine to be used for clinical purposes, (4) reasonable use of its facilities and permits and (5) its expertise and know-how. Pursuant to the JV Agreement, 51% of the interest in the Joint Venture shall initially be owned by the Company and 49% of the interest in the Joint Venture shall initially be owned by ZTI, subject to adjustment in the event of additional contributions by either party. Notwithstanding the foregoing, in no event shall either party own more than 60% of the interest in the Joint Venture. | Pursuant to the terms of the JV Agreement, (A) the Company shall contribute (1) $225,000 and (2) its expertise and the expertise of its science advisory board and (B) ZTI shall contribute (1) certain rights to certain of its patented technology as set forth in the JV Agreement, (2) a license to the know-how and trade secrets with respect to its Z-pod™ technology for the loading and release of ketamine, (3) ketamine to be used for clinical purposes, (4) reasonable use of its facilities and permits and (5) its expertise and know-how. Pursuant to the JV Agreement, 51% of the interest in the Joint Venture shall initially be owned by the Company and 49% of the interest in the Joint Venture shall initially be owned by ZTI, subject to adjustment in the event of additional contributions by either party. Notwithstanding the foregoing, in no event shall either party own more than 60% of the interest in the Joint Venture. |  |

X
- References No definition available. + Details
Name: | silo_AggregateOfConvertedShares
Namespace Prefix: | silo_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | silo_AgreementDescription
Namespace Prefix: | silo_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | silo_AgreementShallExpire
Namespace Prefix: | silo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | silo_CashReceived
Namespace Prefix: | silo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- References No definition available. + Details
Name: | silo_CommercialSaleTerm
Namespace Prefix: | silo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | silo_CommitmentsandContingenciesDetailsLineItems
Namespace Prefix: | silo_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | silo_CompanyPaidCash
Namespace Prefix: | silo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | silo_ConsiderationFeePayablePercentage
Namespace Prefix: | silo_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | silo_DeferredRevenueLongtermPortion
Namespace Prefix: | silo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Deferred revenue long-term portion amounted. + References No definition available. + Details
Name: | silo_DeferredRevenueLongtermPortionAmounted
Namespace Prefix: | silo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | silo_EmploymentAgreementDescription
Namespace Prefix: | silo_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition First commercial sale. + References No definition available. + Details
Name: | silo_FirstCommercialSale
Namespace Prefix: | silo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | silo_LicenseAgreementDescription
Namespace Prefix: | silo_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | silo_LicenseAgreementExpire
Namespace Prefix: | silo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fee incurred and are directly related to generating license Expenses. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. + References No definition available. + Details
Name: | silo_LicenseFee
Namespace Prefix: | silo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | silo_LicensorShare
Namespace Prefix: | silo_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | silo_NetSalePercentage
Namespace Prefix: | silo_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | silo_NonrefundableCashPayment
Namespace Prefix: | silo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | silo_NumberOfVotingShares
Namespace Prefix: | silo_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other. + References No definition available. + Details
Name: | silo_OtherDepreciationsAndAmortization
Namespace Prefix: | silo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | silo_PaymentDescription
Namespace Prefix: | silo_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment of sponsored research amount. + References No definition available. + Details
Name: | silo_PaymentOfSponsoredResearchAmount
Namespace Prefix: | silo_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | silo_PaymentOfUniversity
Namespace Prefix: | silo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | silo_PrepaidExpenses
Namespace Prefix: | silo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Pursuant Terms. + References No definition available. + Details
Name: | silo_PursuantTerms
Namespace Prefix: | silo_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | silo_RecognizedRevenues
Namespace Prefix: | silo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | silo_RevenueTerm
Namespace Prefix: | silo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | silo_ReverseStockSplitVoteDescription
Namespace Prefix: | silo_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | silo_RoyaltyPaymentsDescription
Namespace Prefix: | silo_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | silo_SecuritiesReceived
Namespace Prefix: | silo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- References No definition available. + Details
Name: | silo_SponsoredResearchAgreementDescription
Namespace Prefix: | silo_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | silo_SponsoredStudyAgreementDescription
Namespace Prefix: | silo_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | silo_SublicenseAgreementAmountPaid
Namespace Prefix: | silo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Sublicense amount paid. + References No definition available. + Details
Name: | silo_SublicenseAmountPaid
Namespace Prefix: | silo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | silo_SublicenseIncomeDescription
Namespace Prefix: | silo_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage sublicense income. + References No definition available. + Details
Name: | silo_SublicenseIncomePercentage
Namespace Prefix: | silo_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront license fees. + References No definition available. + Details
Name: | silo_UpfrontLicenseFees
Namespace Prefix: | silo_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense for award under share-based payment arrangement. Excludes amount capitalized. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 + Details
Name: | us-gaap_AllocatedShareBasedCompensationExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of cash inflow from customers for revenue related transactions that are refundable to the customers and do not meet the criteria for revenue recognition. + References Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585 + Details
Name: | us-gaap_CustomerRefundableFeesProceeds
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals. Excludes amount related to plans that cover generally all employees (for example, but not limited to, qualified pension plans). + References No definition available. + Details
Name: | us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The compensation expense recognized during the period pertaining to the deferred compensation arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 710 -SubTopic 10 -Section 30 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363 + Details
Name: | us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_DeferredRevenueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized that was previously reported as deferred or unearned revenue. + References No definition available. + Details
Name: | us-gaap_DeferredRevenueRevenueRecognized1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue from insurance services, including net premiums earned, gain on sale of insurance block, agency management fees and insurance contract fees and commissions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.1,4) -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 + Details
Name: | us-gaap_InsuranceServicesRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Carrying amount of the unpaid portion of the fee payable to the managing member or general partner for management of the fund or trust. + References No definition available. + Details
Name: | us-gaap_ManagementFeePayable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of long-term debt classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)) -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878 + Details
Name: | us-gaap_OtherLongTermDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 340 -SubTopic 10 -Section 45 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_OtherPrepaidExpenseCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_PrepaidExpenseAndOtherAssetsCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Carrying amount as of the balance sheet date of amounts paid in advance which will be charged against earnings in periods after one year or beyond the operating cycle, if longer. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_PrepaidExpenseOtherNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585 + Details
Name: | us-gaap_RecognitionOfDeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of recorded unconditional purchase obligation to be paid in remainder of current fiscal year. + References No definition available. + Details
Name: | us-gaap_RecordedUnconditionalPurchaseObligationDueInRemainderOfFiscalYear
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The risk-free interest rate assumption that is used in valuing an option on its own shares. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares purchased for issuance under share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (l) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 + Details
Name: | us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(2) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 + Details
Name: | us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Liability for agreement to continue an employee's salary after termination of employment (but before retirement) including death, disability, or other event. For example, a company may agree to continue a disabled employee's salary for six months. + References No definition available. + Details
Name: | us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of operating expense for depreciation and amortization of regulated operation. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(b)) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227 + Details
Name: | us-gaap_UtilitiesOperatingExpenseDepreciationAndAmortization
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | silo_TypeOfAgreementAxis=silo_SublicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_ColumbiaUniversityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_DrJamesKuoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=silo_AikidoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=silo_MasterLincenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=silo_JVAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |